TargaZyme
Innovative Cell Therapy Efficacy Multiplier Products Aimed at Enabling Cures for Late-Stage Cancer Patients with Potential to Transform the Field of Cell and Gene Therapy

TargaZyme, a leading clinical-stage cancer immunotherapy company, is one of the Top 10 Cell and Gene Therapy Companies of 2023 for developing next-generation, potentially curative cancer immunotherapies aimed at transforming clinical outcomes for late-stage metastatic cancer patients with blood cancers and solid tumor cancers such as lung, breast, colon and pancreatic cancers.

TargaZyme a stealth-mode company, has leapfrogged to the forefront of the cancer immunotherapy field thanks to its fucosylation cell efficacy multiplier platform technology with its proven mechanism of action validated in multiple human and preclinical trials at prestigious U.S. medical institutions, numerous peer-reviewed publications, prestigious medical and scientific awards. The company has now successfully advanced from idea stage to accomplishing a game-changing product portfolio that includes an FDA Phase 3 Special Protocol Assessment TZ 101 cancer supportive care product where Phase 2 human efficacy signal data points to its potential to disrupt and transform the annual $50 billion cancer supportive care market as well as potentially making the curative hematopoietic stem cell transplantation procedure safer and more efficacious for patients with serious autoimmune diseases and blood cancers and disorders. Its FucoTIL product for late-stage cancer patients with solid cancer tumors promises to disrupt the current generation of adoptive cancer immunotherapy products by providing a potentially curative option for late-stage metastatic cancer patients with little to no hope for survival.

“So far, the only adoptive cancer immunotherapy that has been proven clinically to work for treating patients with solid cancer tumors is TIL (tumor infiltrating lymphocyte) therapies albeit with limited efficacy with the exception of melanoma and cervical cancer. “TILs and Fucosylation as separate products has been proven safe and efficacious in Phase 2 clinical trials. Our FucoTIL product is essentially a combination therapy of these two clinically proven products where we are leveraging the synergistic power of TILs with their antigen diversity required for solid cancer tumor killing and our fucosylation TIL efficacy multiplier product which superboosts TIL solid cancer tumor killing effectiveness with the goal of eradicating patients’ cancers” said Lynnet Koh, CEO and Founder of TargaZyme.

For patients with solid cancer tumors undergoing adoptive cell therapies, higher numbers of adoptive immune cells with antigen diversity reaching the patients’ tumor sites are correlated with improved clinical outcomes. Efficacy outcomes for the current generation of TIL therapies are constrained by the inefficient trafficking or homing of the immune cells from IV infusion through the vasculature and eventual entry into tumor sites where today, less than 3 percent of infused immune cells reach tumor sites with minimal intra-tumoral penetration. TargaZyme’s cell efficacy multiplier product enables 250-500% more TILs to be ‘delivered’ from the vasculature to the tumors with a correspondingly multi-fold increase in intra-tumoral penetration essentially enabling the increased numbers of TILs, i.e. ‘soldiers’ to mount more effective attacks against the solid cancer tumors for their obliteration. Interestingly, TargaZyme cell efficacy multiplier technology also supercharges FucoTILs’ solid tumor-killing machinery by enabling the increased expression of Granzyme B, Perforin, and FASL, thus improving the immune response as the cell synapse with solid tumors, all of which contributes to the increased potency of Targazyme’s FucoTILs to more effectively eradicate solid cancer tumors.

TargaZyme’s most clinically advanced Phase 3 Special Protocol Assessment TZ 101 product also targets late-stage patients although with different diseases such as blood cancers, serious autoimmune diseases, blood disorders. An off-the-shelf product that is simple to use and administer at ‘bedside’, TZ 101 has demonstrated its potential in Phase 2 clinical trials to potentially disrupt the $50 billion per year cancer supportive care industry by potentially preventing/reducing the incidence of multiple life-threatening side effects associated with intense chemotherapy/hematopoietic stem cell transplantation.

Today, a patient receiving a hematopoietic stem cell transplant aimed at curing late stage blood cancer, serious autoimmune diseases such as multiple sclerosis and lupus, blood disorders such as sickle cell anemia and thalassemia will receive a vast (over ten, easily 20+) cocktail of drugs (Neulasta, Nplate, anti-viral drugs, antibiotics, anti-fungal drugs, anti-acute GvHD drugs, anti-cGVH drugs, medicine to treat low red blood cell count, medicine to treat internal bleeding, drugs to treat veno-occlusive disease, drugs to treat engraftment failure, various organ failure, etc. all with their associated costs and side effects, just to treat the various side effects of standard-of-care treatment. Phase 2 clinical trials and preclinical testing data at MD Anderson Cancer Center have demonstrated the potential of TZ 101, i.e. just one drug candidate to accelerate both myeloid and lymphoid cell recovery post intense chemotherapy and reduce the risks of various life-threatening side effects associated with hematopoietic stem cell transplantation, such as viral, bacterial and fungal infections, GvHD versus host disease, hemorrhaging, engraftment failure rate, etc.

TZ 101’s competitive advantages include its demonstrated potential to help prevent multiple post-transplant life-threatening morbidities versus competitive products that deliver efficacy for a single morbidity, with its remarkable simplicity with ease of use and administration. This innovative solution enables treating diverse cell types within a mere 30-minute timeframe, at room temperature. Its user-friendly nature eliminates the necessity for additional staff or specialized equipment, facilitating immediate administration either at the bedside or as an integral step in the manufacturing process of therapeutic cells. This efficient and accessible approach not only ensures timely treatment for terminally ill patients but also eliminates the waiting time associated with life-saving therapies.

While TZ 101, as a cell efficacy multiplier product platform, has the potential to transform multiple areas of medicine, TargaZyme’s first and overarching goal with TZ 101 is to improve the safety and efficacy of hematopoietic stem cell transplantation and enable its vision of this curative treatment to be transformed from the treatment of last resort for patients with late-stage blood cancers and life-threatening autoimmune diseases to more of a front-line therapy.

TargaZyme’s unwavering pursuit of scientific excellence is evident through its extensive intellectual property portfolio. With over 30 patents awarded worldwide and an impressive 35 pending patent applications, TargaZyme showcases its commitment to driving innovation.

TargaZyme is open to partnering its cell therapy efficacy multiplier product with adoptive cell therapy companies focused on curing cancer with CAR-T, TCR, and NK cell therapies, helping them achieve improved efficacy outcomes for cancer patients. TargaZyme is also open to partnering its cell therapy efficacy multiplier product with adoptive cell therapy companies developing Treg therapies to cure autoimmune diseases.

Through its cell therapy efficacy multiplier products, TargaZyme hopes to help transform the cell and gene therapy field. It aims to create a reality where cancer patients can be effectively cured with the power of their own immune systems without all the highly toxic side effects of standard-of-care cancer therapies.